Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Completed 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1872Neoplasms 1257Colorectal Neoplasms 1059Carcinoma, Non-Small-Cell Lung 1012Stomach Neoplasms 803Carcinoma, Hepatocellular 785Lung Neoplasms 769Prostatic Neoplasms 697Pancreatic Neoplasms 577Rectal Neoplasms 450Ovarian Neoplasms 406Neoplasm Metastasis 405Colonic Neoplasms 405Uterine Cervical Neoplasms 400Recurrence 383Leukemia, Myeloid, Acute 372Esophageal Neoplasms 363Multiple Myeloma 340Lymphoma 335Head and Neck Neoplasms 330Melanoma 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 292Brain Neoplasms 264Urinary Bladder Neoplasms 256Liver Neoplasms 225Nasopharyngeal Carcinoma 223Leukemia 218Lymphoma, Large B-Cell, Diffuse 216Polycystic Ovary Syndrome 210Squamous Cell Carcinoma of Head and Neck 205

Interventions

tanezumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Schwannomatosis × Clear all
NCT04163419 2024-03-13

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

Massachusetts General Hospital

Phase 2 Unknown
9 enrolled

Schwannomatosis, Neurilemmoma, Hereditary Sensory and Autonomic Neuropathies, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡